What the pulmonary specialist should know about the new inhalation therapies.
about
Diagnosing COPD: advances in training and practice - a systematic reviewInhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT)Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientPharmacotherapy in the management of asthma in the elderly: a review of clinical studiesSwitching treatments in COPD: implications for costs and treatment adherenceImpact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.Asthma control: the right inhaler for the right patientTopical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosolsComparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study.Effect of inhaler design variables on paediatric use of dry powder inhalersCharacteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting.Small airway dysfunction and bronchial asthma control : the state of the artFundamentals of aerosol therapy in critical careEffects of aclidinium on determinants of COPD severity: symptoms and quality of lifeA review of nebulized drug delivery in COPDA budget impact analysis of Spiromax(®) compared with Turbuhaler(®) for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish HealthDevelopment of an ex vivo human-porcine respiratory model for preclinical studies.The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.International consensus on (ICON) pediatric asthmaConcept review of dry powder inhalers: correct interpretation of published data.Polymeric nanocarriers for transport modulation across the pulmonary epithelium: dendrimers, polymeric nanoparticles, and their nanoblendsRecent advances in capsule-based dry powder inhaler technology.MRI-based measurements of aerosol deposition in the lung of healthy and elastase-treated rats.Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update.High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.Comparison of numerical simulations to experiments for atomization in a jet nebulizer.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study.Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre studyInhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.Plume Characteristics of Two HFA-Driven Inhaled Corticosteroid/Long-Acting Beta2-Agonist Combination Pressurized Metered-Dose Inhalers.Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?A modified nebulization modality versus classical ultrasonic nebulization and oxygen-driven nebulization in facilitating airway clearance in patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trialHow to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze.The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries.Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.Aerosol deposition in health and diseaseValidation of scores of use of inhalation devices: valoration of errors.Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.
P2860
Q26751313-980F6EF0-7878-4773-8010-FB3F1D3E3724Q26751471-B85F6D88-0B2F-44FC-8698-D03637DD5472Q26752680-A303EFE1-BED6-4789-A694-BF48702ABC41Q26769046-4BB69B41-5A75-48A2-BA56-36CDA4050664Q26776324-9BE7B85E-AA32-49BE-8C00-1EF1BEF59750Q26826860-76EB450A-100B-4B78-BB6E-1B5CCF51DC7CQ26863778-877258FB-F13E-43CF-9F5E-C51B113FC849Q27305954-39D9CB29-3955-42C8-80D2-2CC590AB69C4Q27309809-314D4B6E-EE43-47AD-844F-EA487F88F8EEQ27324278-F9717A69-5894-48E3-AB85-F13ABCA448F1Q27334822-B4943B42-50E0-461B-9FF0-40FCD0F4F263Q28067594-28C74089-85FA-467E-A025-3AA215A8E4D9Q28068836-62A98103-2A00-4B62-A238-211EF2644790Q28069533-53172C65-B139-4A40-9D20-7820875CC29AQ28075295-83E6B946-0A9D-489C-86FD-9B984DEFD6B7Q28389109-8BD61CB9-E985-44FD-B053-9C0CA576E1F2Q29247899-A28F770E-1A2A-4A10-91A3-B08BDB39438BQ30366176-FD12F064-B583-44E6-BD8F-B36B8A9BAA98Q30393965-EF9518F5-CE59-46D8-98E2-3CEC406B1BD5Q31030099-4879E4FF-F1BF-430A-84A4-696B58F49226Q33574188-E945A588-4645-4483-82E1-74152174D4D8Q33711473-D9A71FE7-FF0A-4116-AF7A-670573B60124Q33781355-F70E8130-DC3F-47F2-AF2B-4150CB99B793Q34247921-0E8FFE15-84B0-4196-8427-C6D168305AD8Q34433909-CF9BA379-BC90-4BF4-8927-51ED6031D216Q34577430-6D0CB127-6AED-4398-BADD-B24E287B6938Q35045406-0750F912-EFDC-47DC-BD7D-69393BF644D2Q35538249-D248CFB8-EF97-49CC-8D47-B8731C27E36CQ35545567-3958F5CF-B272-4866-8190-8CFC644B39B3Q35556510-089B035C-AAF5-44D4-8545-4FD4B79E1035Q35618690-E9C12C19-81A6-496A-BCBE-F892D9884678Q35671319-E0AF7CA6-9CB6-47E1-AABA-F6EB6C5D37B5Q35691050-268E1820-2B40-49F0-B750-67C34EADD3DEQ35909235-4B6E97EE-9230-4F39-811C-DC79D65BD50CQ35939339-6DD6F4BE-C0E5-4F95-9861-83A692FA166CQ36074295-FE6D011A-AB2A-4642-A180-D6AAC1E95BACQ36141290-F25D2FE9-692C-4577-AB4D-BA3BE891FE93Q36158504-D22B6581-C280-4CEF-B0DB-B32996E4489FQ36256586-4221750F-B205-4799-ADE8-171D49A30616Q36374382-A495EA0E-1A9C-4F68-B89C-C027859B0325
P2860
What the pulmonary specialist should know about the new inhalation therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What the pulmonary specialist should know about the new inhalation therapies.
@en
What the pulmonary specialist should know about the new inhalation therapies.
@nl
type
label
What the pulmonary specialist should know about the new inhalation therapies.
@en
What the pulmonary specialist should know about the new inhalation therapies.
@nl
prefLabel
What the pulmonary specialist should know about the new inhalation therapies.
@en
What the pulmonary specialist should know about the new inhalation therapies.
@nl
P2093
P50
P1476
What the pulmonary specialist should know about the new inhalation therapies.
@en
P2093
F H C de Jongh
H Chrystyn
H M Janssens
International Society for Aerosols in Medicine
M L Everard
S G Devadason
P304
P356
10.1183/09031936.00166410
P577
2011-02-10T00:00:00Z